Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy prior to administration of pafolacianine. Discontinue folate, folic acid, or folate containing supplements 48 hours before administration of pafolacianine. Pafolacianine is not approved for use in patients with cancer in the lung.
- TRADE NAME: Cytalux (On Target Labs)
- INDICATIONS: Optical imaging agent for use in fluoresence-guided surgery. Indicated in adult patients with ovarian cancer.
- SYNONYM: Pafolacianine sodium
- CLASS: Diagnostic aid, Optical imaging agent
- HALF-LIFE: 0.4 hours
- FDA APPROVAL DATE: 11/29/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Pafolacianine may cause fetal harm when administered to a pregnant woman.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
